Preparing to launch. The first report is in development.
Dutta Biotech Research examines the scientific evidence behind biotech therapies, beginning with neuroscience.
It is written for professional investors and experienced individual investors who want to understand what a candidate’s evidence establishes, how strong the conclusions are, and which questions remain unanswered.
Each report starts with a consequential scientific question. We examine the biological rationale, preclinical evidence, clinical trial design, results, safety findings, and relevance to patients. Where public evidence permits, we build original comparisons, reconstruct reported analyses, or reanalyse public data. Conclusions link to their sources and address the strongest competing interpretation.
Scientific assessment is the product. Readers make their own investment decisions. Reports use qualitative scenarios and observable evidence that would change the assessment; they do not provide valuations, price targets, trading recommendations, or numerical forecasts of approval.
Research before the decision
Prospective coverage focuses on neuroscience therapeutics with a disclosed FDA target action date. We select programs where sufficient public evidence supports a useful original assessment.
We will publish each prospective report at least one calendar month before the target date disclosed at publication. FDA dates can change, and decisions can arrive early. Reports identify the source and date of the target, their evidence cutoff, and their promised public-release time. Important new evidence receives dated updates.
Paid first. Public afterward.
At launch, subscriptions will cost $100 per month or $1,000 per year. Paid readers will receive the full prospective research, original comparisons and source-linked evidence dossiers, and substantive updates.
The preserved original becomes public at the earliest of the decision’s verified public disclosure, verified withdrawal or cancellation of the covered application, or its originally advertised release time. An extension does not postpone that release.
The public record will include every published report, dated changes and corrections, and assessments that prove mistaken, mixed, or unresolved. We evaluate scientific claims separately from the FDA’s disposition of an application.
About the author
I’m Dipankar J. Dutta, PhD. I earned my neuroscience doctorate at the Icahn School of Medicine at Mount Sinai and subsequently conducted research at NIH, Children’s National, and Gladstone. My research has included myelin biology, neural conduction, and Alzheimer’s disease.
I use AI tools to assist with retrieval, analysis and drafting. I examine key source evidence, lead the scientific interpretation and editorial judgment, and take responsibility for the published work.